Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like New technique offers real-time glioblastoma monitoring September 30, 2024 New AI model forecasts glucose changes in type 1 diabetes patients September 9, 2026 New technique rapidly tracks cell state changes through density measurements May 21, 2025